Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Restructured By A Planned Reverse Merger

http://investorshub.advfn.com/boards/post_reply.aspx?message_id=116422935

The new name...The new company...Onko Result Diagnostik A.S. ...Pharmaline was our distributor before we gave Uni-Pharma the Turkey Territory..Why did Pharmaline decide to start a new subsidiary and focus on DR-70? According to the information, they had been implementing Clinical Trials for the last two to three years and it "exceeded its expectations."The distributorship with Uni-Pharma is exactly the plan laid out in the Pharma Board interview and the Distributorship agreement between Radient/AMDL Diagnostics Inc. and Uni-Pharma.

Onko Result Diagnostik A.S.

http://www.onkoresult.com.tr/iletisim.html
https://www.facebook.com/onkoresult

http://pharmaline.com.tr/index.html

"Every Picture Tells A Story" Don't It?

http://uni-pharma.com/news_detail-2.html

???DR-70 ??? ONKOResult ??
2015/04/08

?????OnkoResult ( Pharmaline ???) ?????????DR-70 ????,??????,????????????????;???????????,???????,?????????????????????????,??????????,?????????DR-70 ??????

Turkey DR-70 total distribution ONKOResult visit
2015/04/08

Turkish company OnkoResult (Pharmaline subsidiary) in the past two to three years to implement DR-70 clinical trials, the results exceeded expectations, supported by many local doctors and teaching hospitals; April in particular to the company visits, negotiated distributor matters, will actively Government budget execution for people tracking and screening program for colorectal cancer, and gradually applied to other cancers, and help the company to promote the DR-70 to neighboring countries.

TL: In 2010, thanks to Freia’s help, we added a cancer-detection device—an in-vitro diagnostics (IVD) product—to our portfolio. The device is extremely efficacious in monitoring the progress of colorectal cancer treatment.

But our plans do not stop at Taiwan!

Freia Wei (FW): Based on our work with this product so far, we further gained the right to manufacture it in Taiwan. We are looking to transform our company from a pure distribution player to an organization that has the capability to make and develop its own products.

We don’t want to be confined by such vagaries—we want to own our products, and we want to be able to move beyond Taiwan. To this end, we have recently established a manufacturing and distribution partnership with the company Pharmigene.

As Freia began to mention, we are now looking to differentiate our business and move beyond distribution. To do so, we plan to increase our capital, and significantly expand our organization, over the next two years.

We need a partner to help us manufacture the product, which is why we have formed an alliance with Pharmigene. This way, we will not need our own factory for production purposes.

FW: Our vision is to take this product to different countries. We think Onko-Sure can benefit patients throughout the entire world. We own the license to manufacture it in Taiwan, and to sell it in a number of global markets, mostly in Asia Pacific and the Middle East. Penetrating these markets—our first international foray with a product we manufacture ourselves—will be a huge step for us.

After we take that first step, we will look to develop an even better product. Our dream is to do more with diagnostics for cancer patients. We want to develop an increasingly broad portfolio that is tailored to that goal. Will it come to define us as a company? That depends on how successful we are!

FW: The product is unique. Onko-Sure uses a biomarker that is significantly underutilized. If we can bring it to the market with the right strategy, we will gain market share very quickly. A number of countries have already expressed strong interest in offering Onko-Sure within the parameters of their health insurance systems.

With that said, one challenge that we will face overseas is the diversity of regulation, and the fact that we will need a tailored pricing strategy for each country. Pricing is critical, and we know that we cannot homogenize price across every market we enter. We will also need the right partners to help us along the way: at this time, we are not in a position to open our own international branches.

Our long term strategy and consideration for profit has given us a self-pay focus in Taiwan. However, we will respond to partner demand in countries like Turkey, Australia, and China when we bring Onko-Sure to those markets. We will reduce price, and give our distribution partners more space to be competitive and submit for reimbursement.

TL: I think we will have grown the company ten-fold: both in terms of staff count and revenues. We will need more people to understand the subtleties inherent in different international regulatory systems—and at the same time, our ventures outside of Taiwan will bring increased turnover. By 2018, Uni-Pharma will be present in more than ten countries, and the next generation of our product will be on the market.

FW: We are also planning an IPO. As you can imagine, developing our own product internationally will be a very capital-intensive endeavor.

TL: We anticipate an IPO around 2016. We hope to raise about NT$300 million.

There are multiple reasons for our evolution. Firstly, I think it was the right time. The company was looking for a new direction, and Onko-Sure had the right profile. With a pharmaceutical product, we would have had a hard time in Taiwan because of the challenges we would face in development and regulation. For diagnostic products, Taiwan has had significant strengths for at least ten years in OEM. By leveraging that history, and with the great partner that we have in Pharmigene, we can make great strides forward.

Taiwan is a small island. Every company has their unique strengths, but we need to team up in order to grow.

TL: We’ve completed our first steps in developing a manufacturing platform in Taiwan. The second step is now to work with our partner to study the regulations in different Asian markets. We believe our first achievements will trickle down in 2014: we hope to receive marketing approval in four or five countries by the end of that year.


http://pharmaboardroom.com/interviews/interview-terry-lin-general-manager-and-freia-wei-senior-consultant-uni-pharma/

4$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

AMDL Australia has become Cancer Screen Technologies....Will Jade be the China distributor or CST? Uni-Pharma is not developing the next generation DR-70..That is being done by Provista Diagnostics..Who will be the distributor in USA? According to the lSA it will be Provista Diagnostics. Who will be the international
distributor for Provista's Breast, Ovarian, lung cancer tests? Uni-Pharma. Look for Uni-Pharma and Provista to mutually take the Radient Shell..This appears to be the plan since 2009 you understand.imo Wolf ahooooooooooooooooooooooooooooooooooooooooooo


"Our long term strategy and consideration for profit has given us a self-pay focus in Taiwan. However, we will respond to partner demand in countries like Turkey, Australia, and China when we bring Onko-Sure to those markets."

http://pharmaboardroom.com/interviews/interview-terry-lin-general-manager-and-freia-wei-senior-consultant-uni-pharma/

November 2, 2010) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has entered into an exclusive 5-year Laboratory Services Agreement (LSA) with Provista Diagnostics Inc. (Provista). Provista conducts diagnostic research and provides CLIA laboratory developed tests and services to the general public.

Under the terms of the LSA, Provista will have the exclusive rights in the U.S. to develop and market CLIA laboratory developed tests (LDTs) for cancer screening purposes using RPC's proprietary polyclonal antibodies for fibrin and fibrinogen degradation products (FDP).

According to Douglas MacLellan, Executive Chairman and CEO of Radient Pharmaceuticals, "Collaboration with Provista is a natural fit for us. They have a strong, long-standing reputation for providing state-of-the-art CLIA testing services. In forging this relationship, Radient will be securing a new laboratory services and testing distribution channel for its products and we are extremely excited to expand a relationship between our two firms."

The LSA provides for both minimum quarterly antibody purchases from RPC and for RPC to share in the net proceeds from the sale of any LDTs that are developed by Provista from RPC's proprietary FDP antibodies.

Provista CEO William Gartner commented, "We have already successfully brought one cancer screening test to the market called the BT Test, which is a highly accurate blood test for the detection of breast cancer in women. Under our agreement with RPC we will actively pursue the development of new cancer screening and detection assays using RPC's proprietary FDP antibodies." According to Gartner this also includes accelerating the market introduction of a very sensitive FDP-derived CLIA laboratory developed test for lung cancer screening.

http://www.marketwired.com/press-release/Radient-Pharmaceuticals-Announces-Exclusive-5-Year-Laborat
ory-Services-Agreement-With-NYSE-Amex-RPC-1345331.htm